https://silexion.com/ https://silexion.com/about https://silexion.com/science https://silexion.com/publications https://silexion.com/press-releases https://silexion.com/investors https://silexion.com/investors/sec-filings https://silexion.com/investors/stock-information https://silexion.com/investors/committee-composition https://silexion.com/investors/analyst-coverage https://silexion.com/investors/presentations https://silexion.com/investors/alerts https://silexion.com/accessibility-statement https://silexion.com/press-releases/slxn-20260909-silexion-therapeutics-to-participate-in-september-2026-indus2026-09-09 https://silexion.com/press-releases/slxn-20260814-silexion-therapeutics-reports-second-quarter-2026-financial2026-08-14 https://silexion.com/press-releases/slxn-20260812-silexion-therapeutics-announces-pricing-of-25-million-public2026-08-12 https://silexion.com/press-releases/slxn-20260804-silexion-therapeutics-reports-new-positive-preclinical-findi2026-08-04 https://silexion.com/press-releases/slxn-20260729-silexion-therapeutics-successfully-initiates-phase-23-clinic2026-07-29 https://silexion.com/press-releases/slxn-20260623-silexion-therapeutics-receives-approval-from-germanys-bfarm2026-06-23 https://silexion.com/press-releases/slxn-20260616-silexion-therapeutics-to-attend-bio-international-convention2026-06-16 https://silexion.com/press-releases/slxn-20260526-silexion-therapeutics-announces-1-for-10-reverse-share-split2026-05-26 https://silexion.com/press-releases/slxn-20260518-silexion-therapeutics-reports-first-quarter-2026-financial-r2026-05-18 https://silexion.com/press-releases/slxn-20260515-silexion-therapeutics-announces-exercise-of-warrants-for-1-m2026-05-15 https://silexion.com/press-releases/slxn-20260514-silexion-therapeutics-reports-positive-preliminary-immunothe2026-05-14 https://silexion.com/press-releases/slxn-20260513-silexion-therapeutics-announces-initiation-of-gmp-clinical-s2026-05-13 https://silexion.com/press-releases/slxn-20260428-silexion-therapeutics-announces-successful-submission-of-pha2026-04-28 https://silexion.com/press-releases/slxn-20260324-silexion-therapeutics-receives-approval-from-israeli-ministr2026-03-24 https://silexion.com/press-releases/slxn-20260317-silexion-therapeutics-reports-fourth-quarter-and-full-year-22026-03-17 https://silexion.com/press-releases/slxn-20260305-silexion-therapeutics-urges-shareholders-to-vote-ahead-of-ma2026-03-05 https://silexion.com/press-releases/slxn-20260121-silexion-therapeutics-to-attend-7th-annual-rnai-based-therap2026-01-21 https://silexion.com/press-releases/slxn-20260106-silexion-therapeutics-releases-ceo-letter-to-shareholders-hi2026-01-06 https://silexion.com/press-releases/slxn-20251216-silexion-therapeutics-announces-submission-of-phase-23-clini2025-12-16 https://silexion.com/press-releases/slxn-20251202-silexion-therapeutics-receives-positive-feedback-from-german2025-12-02 https://silexion.com/press-releases/slxn-20251126-silexion-therapeutics-to-present-at-noble-capital-markets-212025-11-26 https://silexion.com/press-releases/slxn-20251125-silexion-therapeutics-successfully-completes-toxicology-stud2025-11-25 https://silexion.com/press-releases/slxn-20251112-silexion-therapeutics-reports-third-quarter-2025-financial-r2025-11-12 https://silexion.com/press-releases/slxn-20250930-silexion-therapeutics-announces-positive-new-human-cell-line2025-09-30 https://silexion.com/press-releases/slxn-20250925-silexion-therapeutics-regains-compliance-with-nasdaq-listing2025-09-25 https://silexion.com/press-releases/slxn-20250911-silexion-therapeutics-announces-pricing-of-60-million-public2025-09-11 https://silexion.com/press-releases/slxn-20250911-silexion-therapeutics-reports-positive-preclinical-data-demo2025-09-11 https://silexion.com/press-releases/slxn-20250904-silexion-therapeutics-announces-selection-of-contract-resear2025-09-04 https://silexion.com/press-releases/slxn-20250902-silexion-therapeutics-to-present-at-the-upcoming-27th-annual2025-09-02 https://silexion.com/press-releases/slxn-20250812-silexion-therapeutics-reports-second-quarter-2025-financial2025-08-12 https://silexion.com/press-releases/slxn-20250801-silexion-therapeutics-announces-exercise-of-warrants-for-182025-08-01 https://silexion.com/press-releases/slxn-20250731-silexion-therapeutics-announces-new-preclinical-data-showing2025-07-31 https://silexion.com/press-releases/slxn-20250716-silexion-therapeutics-announces-1-for-15-reverse-share-split2025-07-16 https://silexion.com/press-releases/slxn-20250709-silexion-therapeutics-announces-positive-results-in-preclini2025-07-09 https://silexion.com/press-releases/slxn-20250529-silexion-therapeutics-announces-groundbreaking-preclinical-r2025-05-29 https://silexion.com/press-releases/slxn-20250521-silexion-therapeutics-completes-key-preclinical-studies-expl2025-05-21 https://silexion.com/press-releases/slxn-20250513-silexion-therapeutics-reports-first-quarter-2025-financial-r2025-05-13 https://silexion.com/press-releases/slxn-20250423-silexion-therapeutics-announces-collaboration-with-global-th2025-04-23 https://silexion.com/press-releases/slxn-20250328-silexion-therapeutics-unveils-innovative-expanded-developmen2025-03-28 https://silexion.com/press-releases/slxn-20250321-silexion-therapeutics-announces-completion-of-innovative-exp2025-03-21 https://silexion.com/press-releases/slxn-20250318-silexion-therapeutics-reports-full-year-2024-financial-resul2025-03-18 https://silexion.com/press-releases/slxn-20250305-silexion-therapeutics-reports-groundbreaking-positive-initia2025-03-05 https://silexion.com/press-releases/slxn-20250225-silexion-therapeutics-announces-completion-of-initial-study2025-02-25 https://silexion.com/press-releases/slxn-20250129-silexion-therapeutics-announces-exercise-of-warrants-for-332025-01-29 https://silexion.com/press-releases/slxn-20250128-silexion-therapeutics-reports-strong-tumor-growth-reduction2025-01-28 https://silexion.com/press-releases/slxn-20250116-silexion-therapeutics-announces-pricing-of-50-million-public2025-01-16 https://silexion.com/press-releases/slxn-20250115-silexion-therapeutics-announces-additional-promising-preclin2025-01-15 https://silexion.com/press-releases/slxn-20250113-silexion-therapeutics-to-present-sil-204-data-in-kras-driven2025-01-13 https://silexion.com/press-releases/slxn-20241217-silexion-therapeutics-collaborates-with-evonik-on-advanced-s2024-12-17 https://silexion.com/press-releases/slxn-20241210-silexion-therapeutics-appoints-renowned-cancer-therapeutics2024-12-10